DMAC
Diamedica
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
DMAC Profile
Diamedica Therapeutics Inc.
A clinical-stage biopharmaceutical company focused on developing novel recombinant protein therapeutics for the treatment of acute ischemic stroke and chronic kidney disease
Biological Technology
01/21/2000
12/07/2018
NASDAQ Stock Exchange
27
12-31
Common stock
301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305
--
Diamedica Therapeutics Inc., was originally incorporated under the Companies Act (Manitoba) through its articles of association on January 21, 2000. On May 31, 2019, the company continued to exist from the company formed under the CBCA to the province of British Columbia formed under the BCBCA. The company is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with serious diseases. DM199, the lead drug candidate for Diamedica therapy, is the first recombinant (synthetic) form of human tissue kallikrein 1 (KLK1) protein with drug activity to be studied in patients.